Progress in the multidisciplinary treatment of gastrointestinal cancers, impact on clinical practice: Peri-operative management of gastro-esophageal cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Okines, A ^a,b   Cunningham, D ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; TEGAFUR; URACIL;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GASTRECTOMY; HEAD AND NECK CANCER; HUMAN; MICROMETASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ARTICLE; ESOPHAGUS TUMOR; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR;

CHEMOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; HUMANS; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 53449100560     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn440     Document Type: Conference Paper

References (34)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Fujimoto S, Akao T, Itoh B et al. Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Ann Surg 1977; 185: 462-466.
3. Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 1978; 16: 209-216.
4. Nakajima T, Nashimoto A, Kitamura M et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: A randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-277.
5. Nashimoto A, Nakajima T, Furukawa H et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287.
6. Nakajima T, Kinoshita T, Nashimoto A et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94: 1468-1476.
7. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer within S-1, an oral fluoropyrimidine. N Eng J Med 2007; 357: 1810-1820.
8. Lise M, Nitti D, Marchet A et al. Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann Surg Oncol 1995; 2: 495-501.
9. Lise M, Nitti D, Marchet A et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763.
10. Macdonald A Fleming TR, Peterson RF et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
11. Cirera L, Balil A, Batiste-Alentom E et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815.
12. Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
13. Bouche O, Ychou M, Burtin P et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488-1497.
14. Nitti D, Wils J, Dos Santos JG et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006; 17: 262-269.
15. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
16. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
17. Kollmannsberger C, Budach W, Stahl M et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: Two cooperative phase II studies of the AJO/ARO/ACO. Ann Oncol 2005; 16: 1326-1333.
18. Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
19. Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698.
20. Kim MK, Ryu JS, Kim SB et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007; 43: 1385-1391.
21. Hartgrink HH, van de Velde CJ, Putter H et al. Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30: 643-649.
22. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
23. Waters A Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999; 80: 269-272.
24. Boige V JP, Saint-Aubert B, Lasser P et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial, ASCO 2007 Annual Meeting Proceedings Part I. J Clin Oncol 2007: 25 (Abstr 4510).
25. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
26. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
27. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
28. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234.
29. Poplin E, Fleming T, Leichman L et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987; 5: 622-628.
30. Coia LR, Engstrom PF, Paul AR et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991; 20: 29-36.
31. Smith TJ, Ryan LM, Douglass HO Jr et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: A study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 269-276.
32. Bedenne L, Seitz JF, Milan C et al. Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. Gastroenterol Clin Biol 1998; 22: 273-281.
33. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
34. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.